Inflammation in HIV-Infected Patients: Impact of HIV, Lifestyle, Body Composition, and Demography - A Cross Sectional Cohort Study

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Langkilde, Anne ^a   Petersen, Janne ^a   Klausen, Henrik Hedegaard ^a   Henriksen, Jens Henrik ^a   Eugen Olsen, Jesper ^a   Andersen, Ove ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; UROKINASE RECEPTOR; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; DISEASE TRANSMISSION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INFLAMMATION; INTRAVENOUS DRUG ABUSE; LIFE EXPECTANCY; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MUSCLE MASS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SEX DIFFERENCE; SMOKING HABIT; TREATMENT RESPONSE; WAIST CIRCUMFERENCE;

ABSORPTIOMETRY, PHOTON; ADULT; BODY COMPOSITION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; DENMARK; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; LIFE STYLE; MALE; MIDDLE AGED; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SOLUBILITY; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 84870943844     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051698     Document Type: Article

References (41)

1. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, et al. (2006) Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 43: 27-34.
2. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, et al. (2007) Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146: 87-95.
3. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, et al. (2012) Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 26: 335-343.
4. Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, et al. (2011) Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One 6: e22698.
5. Islam F, Wu J, Jansson J, Wilson D (2012) Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med.
6. Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, et al. (2012) Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol.
7. Shiels MS, Cole SR, Kirk GD, Poole C, (2009) A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52: 611-622.
8. Friis-Moller N, Sabin CA, Weber R, d'Arminio MA, El-Sadr WM, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993-2003.
9. Lifson AR, Lando HA (2012) Smoking and HIV: Prevalence, Health Risks, and Cessation Strategies. Curr HIV/AIDS Rep.
10. Larsen MV, Omland LH, Gerstoft J, Larsen CS, Jensen J, et al. (2010) Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study. Addiction 105: 529-535.
11. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, et al. (2010) Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 55: 316-322.
12. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, et al. (2005) Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 54: 2939-2945.
13. Lee JK, Bettencourt R, Brenner D, Le TA, Barrett-Connor E, et al. (2012) Association between Serum Interleukin-6 Concentrations and Mortality in Older Adults: The Rancho Bernardo Study. PLoS One 7: e34218.
14. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, et al. (2010) Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201: 1788-1795.
15. Capeau J, (2011) Premature Aging and Premature Age-Related Comorbidities in HIV-Infected Patients: Facts and Hypotheses. Clin Infect Dis 53: 1127-1129.
16. Blasi F, Carmeliet P, (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3: 932-943.
17. Ostrowski SR, Haastrup E, Langkilde A, Ullum H, Eugen-Olsen J (2009) The uPA/uPAR system and suPAR in HIV infection. In: Massimo A, editor. Soluble factors mediating innate immune responses to HIV infection. Bentham E-Books. 85-110.
18. Sidenius N, Blasi F, (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22: 205-222.
19. Thuno M, Macho B, Eugen-Olsen J, (2009) suPAR: the molecular crystal ball. Dis Markers 27: 157-172.
20. Toldi G, Beko G, Kadar G, Macsai E, Kovacs L, et al. (2012) Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission. Clin Chem Lab Med 0: 1-6.
21. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB, (2008) Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol 80: 209-216.
22. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, et al. (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med.
23. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J, (2006) Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem 52: 1284-1293.
24. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, et al. (2000) Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96: 4091-4095.
25. Langkilde A, Hansen TW, Ladelund S, Linneberg A, Andersen O, et al. (2011) Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. Cancer Epidemiol Biomarkers Prev 20: 609-618.
26. Hansen BR, Petersen J, Haugaard SB, Madsbad S, Obel N, et al. (2009) The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med 10: 378-387.
27. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752.
28. Bonnet E, Delpierre C, Sommet A, Marion-Latard F, Herve R, et al. (2005) Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. J Clin Densitom 8: 287-292.
29. Rodriguez-Arenas MA, Jarrin I, del Amo J, Iribarren JA, Moreno S, et al. (2006) Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses 22: 715-723.
30. Celentano DD, Lucas G, (2007) Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Clin Infect Dis 45Suppl 4: S318-S323.
31. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, et al. (2003) Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 169: 656-661.
32. Lyngbaek S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, et al. (2012) CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol.
33. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, et al. (2004) Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 35: 337-342.
34. Gore-Felton C, Koopman C, (2008) Behavioral mediation of the relationship between psychosocial factors and HIV disease progression. Psychosom Med 70: 569-574.
35. Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, et al. (2011) Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. Eur J Clin Microbiol Infect Dis 30: 761-766.
36. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, et al. (2000) Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356: 1800-1805.
37. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB, (2008) suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART. J Infect 57: 55-63.
38. Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol.
39. Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, et al. (2011) Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV Infection. AIDS.
40. Wei C, El Hindi S, Li J, Fornoni A, Goes N, et al. (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952-960.
41. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, et al. (2005) High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 39: 23-31.